MANGOCEUTICALS, INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
MGRX$0.19-4.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
** Consolidated Statements of Cash Flows**
| For the Year Ended · For the Year Ended | ||||
|---|---|---|---|---|
| December 31, 2024 · December 31, 2023 | ||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||
| Net loss | $(8,707,226) | $(9,212,417) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation | 9,936 | 24,889 | ||
| Issuance of common stock for services | 2,106,265 | 1,530,651 | ||
| Imputed interest expense | - | (6,473) | ||
| Options vested for stock-based compensation | 248,682 | 624,463 | ||
| Loss on sale of assets | 18,387 | - | ||
| Amortization on intangible assets | 721,533 | - | ||
| Operating lease right of use asset | 59,769 | 54,979 | ||
| Inventory obsolescence | 18,501 | - | ||
| (Increase) decrease in operating assets: | ||||
| Inventory | - | (18,501) | ||
| Prepaid expenses | 60,953 | - | ||
| Prepaid expenses - related party | - | (49,208) | ||
| (Decrease) increase in operating liabilities: | ||||
| Accounts payable and accrued liabilities | 696,736 | 107,090 | ||
| Operating lease right of use liabilities | (63,717) | (56,726) | ||
| Payroll tax liabilities | (6,595) | 3,878 | ||
| Other liabilities | (27,000) | - | ||
| NET CASH USED IN OPERATING ACTIVITIES | (4,863,776) | (6,997,375) | ||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||
| Purchases of property and equipment | - | (3,519) | ||
| Sale of assets | 65,000 | - | ||
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | 65,000 | (3,519) | ||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||
| Proceeds from borrowings on notes payable - related parties | - | (78,260) | ||
| Proceeds from borrowings on notes payable | 150,000 | - | ||
| Proceeds from sales of common stock for cash | 1,328,268 | 6,200,000 | ||
| Proceeds from sales of preferred stock for cash | 2,650,000 | - | ||
| Proceeds from exercise of warrants | - | 1,024,500 | ||
| Repayment on notes payable - related party | - | (89,200) | ||
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 4,128,268 | 7,057,040 | ||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | ||||
| End of period | (670,508) | 56,146 | ||
| CASH AND CASH EQUIVALENTS: | ||||
| Beginning of period | 739,006 | 682,860 | ||
| Effects of currency translation on cash and cash equivalents | (9,845) | - | ||
| End of period | $58,653 | $739,006 | ||
| Supplemental disclosure of cash flow information: | ||||
| Cash paid for income taxes | $ | - | $ | - |
| Cash paid for interest | $ | - | $ | - |
| $ | - | $ | - | |
| Supplemental schedule of non-cash investing and financing activities: | ||||
| Issuance of common stock for patent acquisition | $1,344,150 | |||
| Issuance of Series C Convertible Preferred for patent acquisition | $14,210,000 | $ | - | |
| Issuance of common stock for Preferred B dividend | $70,168 | |||
| Issuance of common stock for conversion of Series B Convertible Preferred | $1,133,000 | $ | - | |
| Series C Convertible Preferred accrued dividends | $802,109 | $ | - | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.